Evidence map›Paper›PMID 41113409›Full record

ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025

[Design, Synthesis, and Efficacy Evaluation of a Novel BRD4/HDAC Dual-Target Small-Molecule Inhibitor in Prostate Cancer].

Shuyang Feng, Yanxiang Shao, Kan Wu, Weixiao Yang, Xiang Li

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shuyang Feng/ （ 610041） Department/Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.ORCID 0009-0006-2130-9949
Yanxiang Shao/ （ 610041） Department/Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Kan Wu/ （ 610041） Department/Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Weixiao Yang/ （ 610041） Department/Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Xiang Li/ （ 610041） Department/Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.ORCID 0000-0003-0765-1546

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To design a novel bromodomain-containing protein 4 (BRD4) and histone deacetylase (HDAC) dual-target inhibitor (11b), and to elucidate its therapeutic efficacy and mechanisms in suppressing prostate cancer through epigenetic regulation. Methods: BRD4 and HDAC expression levels were assessed via immunohistochemistry (IHC) using prostate cancer tissue microarrays. The inhibitory activity of 11b was screened across three prostate cancer cell lines, with the half-maximal inhibitory concentration (IC Results: BRD4 and HDAC expression levels were both higher in tumor tissues than those in normal tissues ( Conclusion: The dual-target inhibitor 11b exerts potent antitumor effects in prostate cancer by synergistically modulating the BRD4/HDAC pathways. 11b demonstrates therapeutic efficacy superior to that of the single-target agents SAHA and JQ-1 in suppressing prostate cancer progression, highlighting its potential for clinical translation.

Indexed as

Histone Deacetylase InhibitorsProstatic NeoplasmsTranscription FactorsAnimalsAntineoplastic AgentsAzepinesBromodomain Containing ProteinsCell Cycle ProteinsCell Line, TumorCell ProliferationHistone DeacetylasesHumansMaleMiceMice, NudePC-3 CellsAntineoplastic AgentsAzepinesBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsHistone Deacetylase InhibitorsHistone Deacetylases(+)-JQ1 compoundMAS1 protein, humanProto-Oncogene MasTranscription FactorsTriazolesVorinostatDual-target inhibitorEpigenetic repressionEpigenomicsProstate cancer

Identifiers

PMID41113409
PMCPMC12531021

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.